文献速递炎症性肠病

炎症性肠病患者中Janus激酶抑制剂与肿瘤坏死因子拮抗剂的安全性比较

Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-07-28

基于行政索赔数据库的回顾性队列研究,纳入2016至2023年新使用JAK抑制剂或TNF拮抗剂的IBD患者,比较感染、静脉血栓栓塞和主要不良心血管事件风险。JAK抑制剂总体感染风险较高(HR 1.60),但严重感染、VTE和MACE风险与TNF拮抗剂无显著差异。

要点

  • JAK抑制剂总体感染发生率62.4/100人年,高于TNF拮抗剂的37.4/100人年(HR 1.60)。
  • 严重感染、静脉血栓栓塞和主要不良心血管事件风险在两组间无显著差异。
  • 亚组分析结果基本稳定。

核心结论

  • 在IBD患者的观察性研究中,与TNF拮抗剂相比,JAK抑制剂与严重感染、静脉血栓栓塞或主要不良心血管事件风险增加无关,但总体感染风险较高。

研究设计与样本

  • 回顾性队列研究,使用行政索赔数据库识别2016至2023年间新使用JAK抑制剂或TNF拮抗剂且治疗开始前后至少1年有保险覆盖的IBD患者。
  • 纳入856例JAK抑制剂治疗患者(年龄47±17岁,82%为溃疡性结肠炎)和9422例TNF拮抗剂治疗患者(年龄45±18岁,44%为溃疡性结肠炎)。
  • 采用稳定逆概率治疗加权Cox比例风险模型比较感染、静脉血栓栓塞和主要不良心血管事件风险,并考虑疾病特征、医疗利用、合并症、既往和伴随用药及死亡竞争风险。

主要发现

  • JAK抑制剂组总体感染发生率为62.4/100人年,TNF拮抗剂组为37.4/100人年(HR 1.60;95%CI 1.33-1.93)。
  • 严重感染发生率JAK抑制剂组为4.9/100人年,TNF拮抗剂组为5.4/100人年(HR 0.97;95%CI 0.66-1.44)。
  • 静脉血栓栓塞发生率JAK抑制剂组为1.3/100人年,TNF拮抗剂组为1.2/100人年(HR 0.66;95%CI 0.28-1.57)。
  • 主要不良心血管事件发生率JAK抑制剂组为0.4/100人年,TNF拮抗剂组为0.7/100人年(HR 0.50;95%CI 0.19-1.30)。
  • 基于IBD类型、JAK抑制剂类型、年龄、既往生物制剂暴露、伴随使用皮质类固醇和基线不良事件风险的亚组分析结果基本稳定。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We conducted a retrospective cohort study comparing the safety of Janus kinase (JAK) inhibitors vs tumor necrosis factor-a (TNF) antagonists in patients with inflammatory bowel diseases (IBDs). METHODS: Using an administrative claims database, we identified patients with IBD who were new users of either JAK inhibitors or TNF antagonists between 2016 and 2023 and had insurance coverage for at least 1 year before and after treatment initiation. We compared the risk of infections (overall and serious infections requiring hospitalization), venous thromboembolism (VTE), and major adverse cardiovascular events (MACE) through stabilized inverse probability of treatment weighted Cox proportional hazards model accounting for disease characteristics, health care utilization, comorbidities, prior and concomitant medications, and competing risk of mortality. RESULTS: We included 856 patients treated with JAK inhibitors (age, 47 ± 17 years; 82% with ulcerative colitis [UC]) and 9422 patients treated with TNF antagonists (age, 45 ± 18 years; 44% with UC). JAK inhibitors were associated with higher risk of overall infections (incidence rate, 62.4 per 100 person-years [PY] vs 37.4 per 100 PY; hazard ratio [HR], 1.60; 95% confidence interval [CI], 1.33-1.93), but not serious infections (4.9 vs 5.4; HR, 0.97; 95% CI, 0.66-1.44) compared with TNF antagonists. There was no difference in the risk of VTE (1.3 vs 1.2; HR, 0.66; 95% CI, 0.28-1.57) and MACE (0.4 vs 0.7; HR, 0.50; 95% CI, 0.19-1.30). Findings were largely stable on subgroup analyses based on type of IBD, type of JAK inhibitors, age, prior biologic exposure, concomitant use of corticosteroids, and baseline risk of adverse events. CONCLUSIONS: In an observational study of patients with IBD, JAK inhibitors were not associated with an increased risk of serious infections, VTE, or MACE compared with TNF antagonists, although the overall risk of infections was higher.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Ahuja D, Yeh KH, Patel SB, et al. Comparative Safety of Janus Kinase Inhibitors vs Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases. Clin Gastroenterol Hepatol. 2025. PMID: 40738278. doi:10.1016/j.cgh.2025.06.041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。